Reimbursement Strategy & Submissions
tJûn17 Life Sciences Advisors Market Access Support With Reimbursement
Developing an understanding of today’s global reimbursement paradigms can
be a daunting undertaking. Not only is it critical to understand payer coverage,
coding and payment mechanisms, but the converging nature of these variables
with global regulatory requirements can make this task overwhelmingly complex
to many medical technology companies. Moreover, manufacturers that wish to
commercialize innovative new technologies have a substantially more difficult
time communicating the value of their product(s) to reimbursement organizations.
tJûn17 Life Sciences is exceptionally experienced in this area, and has worked
with dozens of companies to successfully navigate global reimbursement system
pathways. Our company has relationships with hundreds of payers across
the globe, and can utilize these relationships to support the development and execution of successful reimbursement strategies that optimize payment levels.
Value Dossier Submissions Examples to Public & Private Payers
- An operative hysteroscopy system for minimally invasive resection of intrauterine fibroids and polyps
- An RF based intradiscal annulopasty system for use in the spine
- Single and multi-use synovial fluid replacement therapies for treatment of osteoarthritis
- A novel biopolymer based material for use in cartilage repair in the knee and hip
- An in vitro diagnostic kit for optimization of 5-FU therapy for colorectal cancer
- An interventional radiology system for visualization and treatment of liver oncology
- A visually based diagnostic system for detection of breast oncology
Additional tJûn17 Life Sciences Advising Support
- Global cost and comparative effectiveness evaluations for new technologies and products
- Development and implementation of global health and economic outcomes strategies
- Design and implementation of online and on-ground training courses in cost and comparative study design and execution
- Review and assessment of Health Technology Assessments (HTA’s) and their potential impact on technology and product commercialization
- Incorporation of cost and comparative effectiveness and HTA study results into reimbursement dossiers
Learn More
A properly developed life science product reimbursement strategy must, by necessity, include an assessment and operational alignment with its regulatory strategy. Innovation, in and of itself, is not enough for successful commercialization in any geographic area.